Robert M. Anthenelli, MD

Robert M. Anthenelli, MD is Professor of Psychiatry and Neuroscience at the University of Cincinnati, College of Medicine where he directs the Addiction Sciences Division. He also serves as Director for the Tri-State Tobacco and Alcohol Research Center at the University of Cincinnati and Cincinnati Veterans Affairs Medical Center (CVAMC), and is the Director of the Substance Dependence Program at the CVAMC.

Dr. Anthenelli earned his baccalaureate degree from The Johns Hopkins University in Baltimore, Maryland and his MD degree from The Johns Hopkins University School of Medicine. After graduating from medical school, he completed his internship in internal medicine at Mercy Hospital in Baltimore. He did his residency training in psychiatry at the University of California, San Diego (UCSD) School of Medicine in La Jolla, where he also completed a 2-year post-doctoral fellowship in addiction psychiatry research. Prior to moving to Cincinnati, he was an Assistant Professor of Psychiatry at the UCSD School of Medicine and the Founding Director of the Substance Abuse/Mental Illness (SAMI) Program at the San Diego VAMC.

The overarching theme of Dr. Anthenelli’s research is to develop improved treatments for tobacco and alcohol dependence by better understanding the neurobiology of the disorders. His lab group is also interested in the role of the endocannabinoid system in these disorders, and he has extensive experience using a CB1 receptor antagonist as an aid to smoking cessation. Funding for his research is provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse, the Department of Veterans Affairs, and various industry sponsors.

Dr. Anthenelli is the recipient of several honors and awards that includes a Young Investigator award from the American Society of Addiction Medicine. He is a member of the Society for Research on Nicotine and Tobacco, Research Society on Alcoholism, and the International Society for Biomedical Research on Alcoholism. He served on and chaired the Clinical Treatment Grant Review Committee for NIAAA; is Section Editor for the Substance Use Disorders section of Current Psychiatry ; and serves on the Editorial Advisory Boards of Alcohol Research & Health , Journal of Studies on Alcohol and Drugs and the Journal of Addiction Medicine .

H. Bryan Brewer, Jr, MD

H. Bryan Brewer Jr, MD, is the Director of Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute at Washington Hospital Center in Washington, D.C. He was formerly the Chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in Bethesda, Maryland, a position he held from 1976 to 2005.

Dr. Brewer's research led to the elucidation of the first published sequences for the human plasma apolipoprotiens, the initial determination of the metabolism of the plasma apolipoprotiens in normal and hyperlipidemic individuals, and the identification of multiple gene defects leading the generic dyslipoproteinemias. More recently, he has pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of the atherosclerosis.

Dr. Brewer received his medical degree from Stanford University School of Medicine in California. After completing his internship and residency in internal medicine at Massachusetts General Hospital in Boston, Dr. Brewer joined the NHLBI. Additionally, he served as a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States.

A recipient of the J.D. Lane Investigator Award from the U.S. Public Health Service, Dr. Brewer also received the Heinrich Wieland Prize from the Federal Republic of Germany and the Public Health Service Commendation Award, Meritorious Service, and Distinguished Service Medals from the NIH.

Dr. Brewer has published more than 400 original manuscripts and 75 reviews and book chapters on the subjects of genetic dyslipoproteinemias, lipoprotein metabolism, and atherosclerosis. He has served on the editorial boards of several prestigious journals and is currently on the editorial board of the Journal of Biological Chemistry .

Sumner Burstein, PhD

Sumner Burstein, PhD, is Professor of Biochemistry and Molecular Pharmacology at University of Massachusetts' School of Biochemistry and Molecular Pharmacology. He received his BS degree from Massachusetts Institute of Technology in 1953 and his PhD from Wayne State University in 1959. His postdoctoral training includes Fellowships at the Weizmann Institute in 1960, and at Brandeis University in 1961.

Dr. Burstein's research interests include the Mechanism of Action of the Cannabinoids, and Therapeutically Useful Cannabinoids. "Interest in the cannabinoid acid metabolites of THC was revived recently by data we obtained showing that they exhibit some of the properties that are associated with nonsteroidal anti-inflammatory agents (NSAIDs). The acids being nonpsychoactive, were long thought to be without any biological actions of their own. In fact, our findings support the possibility that several effects believed to be due to THC may actually be mediated by the acid metabolites. In addition to helping explain the pharmacology of THC, our findings have suggested a route to the discovery of novel NSAIDs with minimal adverse side-effects, a much sought after goal of pharmaceutical research. Using THC-7-oic acid as a template molecule, we have designed and studied several dimethylheptyl side-chain analogs that show similar anti-inflammatory properties, but at doses as low as 10 to 100 micrograms/kg p.o. The most promising candidate has been named ajulemic acid, which, in addition to its anti-inflammatory actions, shows analgesic properties comparable to morphine in potency but devoid of the undesireable side effects. Ajulemic acid has recently been subjected to initial trials in humans based on its generally low toxicity in a variety of in vitro and animal models, and a Phase I trial where it showed no psychotropic activity. We have also found evidence for the existence of an endogenous cannabinoid acid, NAGly, that arises from the metabolism of anandamide, the endogenous THC. Like the THC acids, NAGly shows analgesic and anti-inflammatory activity."

Daniela Cota, MD

Dr. Daniela Cota is a graduate of University of Bologna School of Medicine (Italy), where she had a scholarship in Endocrinology and Metabolic Disorders. Dr. Cota also obtained a fellowship from the Department of Neuro-endocrinology of the Max-Planck Institute in Munich (Germany), where she started investigating the role of the endocannabinoid system in the regulation of energy balance. From 2004 until 2007, Dr. Cota was a postdoctoral fellow at the Obesity Research Center of the University of Cincinnati, Cincinnati, Ohio.

Dr. Cota is interested in the study of neuronal circuits as well as of intracellular signaling cascades that in the brain are involved in the regulation of food intake and body weight. Dr. Cota is also interested in the impact of those neuronal circuits and systems (such as the ECS) on peripheral metabolism and glucose homeostasis.

Dr. Cota recently moved to the INSERM in France, where she has established her laboratory, focusing on hypothalamic fuel sensing mechanisms regulating energy balance.

Dr. Cota is a member of the American Endocrine Society, of the North American Association for the Study of Obesity (NAASO) and of the European Association for the Study of Diabetes. She recently received the NAASO Young Investigator Award for her studies on new hypothalamic pathways involved in the central regulation of energy balance.

Recent publications include

1. Cota D, Proulx K & Seeley RJ. The Role of CNS Fuel Sensing in Energy and Glucose Regulation. Gastroenterology , 2007; 132(6):2158-68.
2. Cota D, Steiner M, Marsicano G, Cervino C, Herman JP, Grübler Y, Stalla J, Pasquali R, Lutz B, Stalla GK & Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology , 2007; 148(4), 1574-81.
3. Cota D, Barrera JG & Seeley RJ. Leptin in energy balance and reward: two faces of the same coin? Neuron , 2006; 51 (6), 678-80.
4. Cota D, Proulx K, Blake Smith KA, Kozma SC, Thomas G, Woods SC & Seeley RJ. Hypothalamic mTOR signaling regulates food intake. Science , 2006; 312 (5775), 927-30.
5. Pagotto U, Marsicano G, Cota D, Pasquali R & Lutz B. Emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews , 2006; 27, 73-100.
6. Cota D, Tschöp MH, Horvath TL & Levine AS. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Research Reviews , 2006; 51(1), 85-107.
7. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation , 2003; 112, 423-431.

Benjamin F. Cravatt, PhD

Dr. Cravatt is a Professor in the Skaggs Institute for Chemical Biology and the Departments of Cell Biology and Chemistry at The Scripps Research Institute (TSRI). His research group is interested in understanding the role that enzymes play in small-molecule signaling pathways in the nervous system, in particular those involved in endocannabinoid metabolism.  His group also develops and applies proteomic and metabolomic technologies to elucidate the function of enzymes in physiological and pathological processes.

Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a BS in the Biological Sciences and a BA in History.  He then trained with Drs. Dale Boger and Richard Lerner and received a PhD in Macromolecular and Cellular Structure and Chemistry from TSRI in 1996.   Professor Cravatt joined the faculty at TSRI in 1997 as a member of the Skaggs Institute for Chemical Biology and the Departments of Cell Biology and Chemistry.  His honors include a Graduate Fellowship from the National Science Foundation (1992-1995), a Searle Scholar Award (1998-2001), a Technology Review's TR100 Top 100 Young Innovators Award (2002), the Promega Award for Early Career Life Scientists from the American Society for Cell Biology (2002), the Eli Lilly Award in Biological Chemistry (2004), and a Cope Scholar Award (2005).

Vincenzo Di Marzo, PhD

Vincenzo Di Marzo, PhD, was born in Naples, Italy, in 1960. He received his degree in chemistry in 1983 from University of Naples "Federico II," and his PhD in Biochemistry from Imperial College of Science, Technology and Medicine in London in 1988. He is presently Research Director at the Institute of Biomolecular Chemistry of CNR, Pozzuoli, Naples, Italy, where he has been a resident since 1988.

He is also Adjunct Associate Professor at the Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia. From 1994 till 1997 he was the primary investigator of a Human Frontier Science Program research grant to study the biosynthesis and metabolism of the endocannabinoid anandamide. He was also the primary investigator of a 3-year European-funded INTAS research grant awarded to study the immunomodulatory role of endocannabinoids, and was responsible for a unit funded by the Volkswagenstiftung.

In 1995, he founded the Endocannabinoid Research Group, a multidisciplinary and multisite research group in the Naples area devoted to studies of all aspects of endocannabinoid research, of which he is currently the coordinator. He was President of the International Cannabinoid Research Society in 2004-2005, from which he received the Mechoulam Award in 2007 for "outstanding contributions to cannabinoid research". He is also a member of the advisory board of the International Chair of Cardiometabolic Risk of Laval. He is coauthor of more than 300 articles, reviews and book chapters on eicosanoids and endocannabinoids. His current interest is the study of the role of the endocannabinoid system in energy balance, neuroprotection, pain, gastrointestinal function, and cancer.

James Early, MD

Dr. Early, Clinical Associate Professor–Preventive Medicine and Public Health, earned his medical degree at the Indiana University Medical School in Indianapolis, Indiana in 1973. He completed his Internal Medicine training at St. Francis Hospital in Peoria, Illinois, an affiliate of the University of Illinois School of Medicine. He is board certified by the American Board of Internal Medicine. Dr. Early has been active in the department since its inception and helped found the MPH program. He has taught Introduction to Public Health, a number of elective rotations, and most recently developed and taught Obesity and Public Health (PRVM 843).

Dr. Early is the founder of The Prevention and Health Center at the Via Christi Regional Medical Center. Since its founding ten years ago the Center has grown and expanded to be one of the busiest and most successful clinical preventive centers in the nation. The Center now includes medical and surgical weight management programs, a lipid education program, and houses a nationally recognized diabetes education program.

Dr. Early's clinical duties include the management of medically significant obesity and support of pre- and postsurgical patients undergoing obesity surgery. He is also active in corporate health, executive physicals, lipid management consultations, and group counseling with patients at high-risk for cardiovascular disease. His research efforts revolve around obesity, dyslipidemia, the metabolic syndrome, and ambulatory systems of medical care.

Research Interests

• Nutrition and obesity
• Ambulatory medical care systems
• Cardiovascular disease research

Henry Ginsberg, MD

Henry N. Ginsberg, MD, is the Irving Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Irving Institute Clinical and Translational Research at Columbia University Medical Center in New York, New York. He earned his medical degree at the State University of New York Downstate Medical Center in Brooklyn, and completed training in internal medicine in Boston University Service of Boston City Hospital in Massachusetts. Dr. Ginsberg also trained in endocrinology and metabolism at Stanford University in California.

Dr. Ginsberg is principal investigator on Columbia’s new Clinical and Translational Science Award and on two R01 research grants from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute. He is also the co-principal investigator at Columbia University on the ACCORD Trial.

His research interests have focused on the regulation of plasma cholesterol and triglyceride blood levels, particularly the metabolism of apolipoprotein B–containing lipoproteins in cells, mice, and humans. Much of his present work focuses on the interaction between insulin resistance and increased secretion of very-low-density lipoproteins by liver. Very active in clinical research training and education, Dr. Ginsberg is Program Director of Columbia University's NIH-funded Clinical Translational Science Award, which supports a Clinical Research Center, a Master’s Program in Patient Oriented Research, and a K12 Scholars Program. He is also Director of a T32 Training Grant in Arteriosclerosis.

Dr. Ginsberg actively participates in national organizations such as the American Heart Association (AHA) and the American Diabetes Association. He is a Fellow of the AHA Council of Arteriosclerosis, Thrombosis and Vascular Biology, and past Chair of the AHA Leadership Committee. He is also a Fellow of the AHA Council of Nutrition, Physical Activity and Metabolism, Fellow of the American Association for the Advancement of Science, as well as a member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Ginsberg is on the editorial boards of The Journal of Clinical Investigation , Journal of Lipid Research , and Journal of Metabolism . He has authored or coauthored more than 200 articles, reviews, and chapters related to lipids, diabetes, and heart disease.

Allyn Howlett, PhD

Allyn C. Howlett, PhD, is currently Professor of Physiology and Pharmacology at Wake Forest University Health Sciences, and is recognized for the demonstration of the CB₁ cannabinoid receptor and its signal transduction in neuronal cells and brain. Dr. Howlett received her BS in Biochemistry from Pennsylvania State University and PhD in Pharmacology and Toxicology from Rutgers University. Her post-doctoral research in the laboratory of Dr. Alfred G. Gilman at the University of Virginia involved characterization of the first G-protein. She joined the faculty of Saint Louis University, where she rose in academic rank to professor in the Department of Pharmacological and Physiological Science and initiated her research on signal transduction in response to eicosanoid and cannabinoid ligands in cultured neuronal models. Dr. Howlett has been awarded a Pharmaceutical Manufacturer’s Association Foundation Faculty Development Award, a Research Career Development Award from NINDS, a Senior Research Scientist Award from NIDA, and she was the first recipient of the International Cannabinoid Research Society’s Mechoulam Award for outstanding contributions to the field of cannabinoid research. In 2000, Dr. Howlett joined North Carolina Central University’s Julius L. Chambers Biomedical/Biotechnology Research Institute to serve for five years as the founding Director of the Neuroscience of Drug Abuse Research Program funded by a cooperative agreement with NIDA. Dr. Howlett has served as Associate Editor for Experimental Biology and Medicine, and as a member of several NIH study sections. She is the Co-chair of the International Union of Pharmacology Nomenclature Committee Subcommittee on Cannabinoid Receptors, and is a member of the Amer. Soc. Pharmacol and Exper. Therapeutics, the College on Problems of Drug Dependence, the Soc. for Neuroscience, and the International Cannabinoid Res. Soc..

Aron H. Lichtman, PhD

Dr. Aron H. Lichtman earned his PhD under the mentorship of Dr. Michael Fanselow at Dartmouth College in 1989 investigating the neurochemicals substrates of stress-induced analgesia. He was then initiated into the cannabinoid field as a postdoctoral fellow in the laboratory of Dr. Billy Martin at Virginia Commonwealth University (VCU). Presently, he is an Associate Professor at VCU where his NIH-funded research program focuses on elucidating the physiological functions of the endocannabinoid system.

Much of Dr. Lichtman’s research utilizes a collaborative multidisciplinary approach examining the relationship between the pharmacological effects of cannabinoids on behavior and the underlying biochemical/molecular mechanisms. His research has contributed to the knowledge that the enzyme fatty acid amide hydrolase (FAAH) is a critical regulator of anandamide and other fatty acids in vivo; setting an endogenous cannabinoid tone that modulates pain and inflammation. The results of other studies in his laboratory have revealed the neural substrates of cannabinoids on pain and memory. Additionally, he has shown that the endocannabinoid system plays a critical role in the extinction of learned behavior that is associated with aversive memories. Another important area in Dr. Lichtman’s laboratory is investigating the consequences of cannabinoid tolerance and dependence. The ultimate goal of this work is to contribute to the development of therapeutic agents that target the endogenous cannabinoid system to treat various disorders, including pain, cognitive disorders, and addiction.

Kenneth Mackie, MD

Ken Mackie, MD, is the Linda and Jack Gill Chair of Neuroscience and a Professor of Psychology at Indiana University, in Bloomington, Indiana. He received his MD from Yale University in 1984. This was followed by post-doctoral fellowships at Rockefeller University and the University of Washington as well as clinical training at Yale University and the University of Washington. Dr. Mackie is board-certified in Anesthesiology. He was a faculty member in the Departments of Anesthesiology as well as Physiology and Biophysics at the University of Washington from 1992 until 2007; when he took his present position at Indiana University.

Dr. Mackie’s research group uses a variety of approaches and focuses on the regulation of synaptic transmission by endogenous cannabinoids and their interactions with plant-derived cannabinoids, the distribution of the components of the endogenous cannabinoid signaling system, the adaptive responses of cannabinoid receptors to sustained stimulation, and the identification and characterization of novel cannabinoid receptors.

Billy R. Martin, PhD

Billy R. Martin was born in Winston-Salem, North Carolina. He earned his bachelors degree from the University of North Carolina at Chapel Hill and then worked as a chemist at the Research Triangle Institute in North Carolina, and later as a research analyst at The University of North Carolina at Chapel Hill. He earned his doctorate in Pharmacology from the University of North Carolina in 1972. He then did post-doctoral work at Uppsala University in Sweden and Oxford University in England before joining the faculty at Virginia Commonwealth University in the Department of Pharmacology.

Dr. Martin rose through the ranks to his current position as Louis and Ruth Harris Professor of Pharmacology and Chairman of the Department. Dr. Martin is world renowned for his research into the biological basis of drug addiction. Understanding addiction, the actions of drugs of abuse, and how they effect the brain have been the themes of Martin's research. In the 1970s he demonstrated for the first time that the marked tolerance that developed to the active constituents was a true pharmacological tolerance at the neuronal level in the brain and not due to an alteration in distribution or metabolism as had been hypothesized. He further showed that the actions of marijuana are attributable to the compound delta-9 THC and not a metabolite. His recently published findings demonstrate for the first time that marijuana produces physical dependence. 

Dr. Martin is a past President of The College on Problems of Drug Dependence (CPDD) and The International Cannabinoid Research Society (ICRS). He also is the recipient of the National Institutes of Health prestigious MERIT award, and the principal investigator of a center and a program project grant from NIH. Martin's advice is sought nationally and internationally from the people setting policy for marijuana control as he is considered as an exponent of a balanced position between therapeutic usefulness and abuse potential. He has been a consultant for the Partnership for a Drug Free America, advisor for the World Health Organization, and a member of the Institute of Medicine's Marijuana Advisory Panel. His work has been featured on the network television shows "Prime Time Live" and "48 Hours." He has also worked with middle and high school students, and is responsible for developing and running a pharmacology class at the local Math and Science High School.

Timothy E. McGraw, PhD

Timothy McGraw, PhD is a Professor of Biochemistry at the Joan and Sanford I. Weill Medical College at Cornell University. He received his PhD from New York University in 1985, then went on to serve as a Fellow of the National Institutes of Health from 1986 to 1989. From 1992 to 1995, Dr. McGraw served as Junior Investigator for American Heart Association, as well as on the advisory committee on personnel for research at the American Cancer Society from 1993 to 1995. In 2002, he became a Member of Cell Structure and Metastasis Study Section of the American Cancer Society. Since 1999, Dr. McGraw has served as a member of P01 review groups and ad hoc member of the Metabolism study section, NIDDK. He is also a member of the American Society for Cell Biology, the American Association for the Advancement of Science, and the American Diabetes Association

Research Interests

"Insulin regulates the storage of dietary glucose by stimulating its uptake into muscle and fat. Insulin increases glucose uptake into these cells by recruiting vesicles containing the GLUT4 glucose transporter to the cell surface. Thus, insulin controls glucose uptake by regulating GLUT4 trafficking between the interior and cell surface. Understanding how insulin regulates GLUT4 traffic is key for understanding the molecular changes underlying type 2 diabetes. We use quantitative optical microscopy to study insulin-regulated membrane trafficking. The main objectives of our work are to characterize the GLUT4 trafficking pathway in the presence and absence of insulin, and to identify how the insulin-signal transduction regulates the movement of GLUT4 vesicles. In addition to studies of GLUT4 trafficking, I am also interested in more basic questions of membrane trafficking, specifically a more detailed understanding of the molecular mechanisms of clathrin-mediated internalization from the cell surface and the mechanisms for return of endocytosed proteins back to the plasma membrane."

Patricia H. Reggio, PhD

Dr. Patricia H. Reggio is Marie Foscue Rourk Professor and Head of the Department of Chemistry and Biochemistry at University of North Carolina at Greensboro. Dr. Reggio is a past President of the International Cannabinoid Research Society. Since 1985, she has had research support from the National Institutes of Health/National Institute on Drug Abuse for her project entitled Molecular Determinants of Cannabinoid Activity. The long-term goal of this research project is to elucidate the basis for the actions of the cannabinoids (CBs) at the molecular level. To this end, her project aims to develop the elements of an understanding of the relationships between cannabinoid ligand structure, cannabinoid receptor structure, and cannabinoid receptor activation at an atomic level of detail.

Roger Pertwee, PhD

Roger Pertwee has three degrees from the University of Oxford: MA (in biochemistry), DPhil (in pharmacology) and DSc (in physiological sciences). He is Professor of Neuropharmacology at the University of Aberdeen, Director of Pharmacology for GW Pharmaceuticals, Co-chair of the International Union of Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors, International Secretary of the International Cannabinoid Research Society, a coordinator of the British Pharmacological Society’s Special Interest Group on Cannabinoids and visiting Professor at the University of Hertfordshire. Roger Pertwee has served two terms as President of the International Cannabinoid Research Society (2007-2008; 1997-1998) and is a past First Chairman of the International Association for Cannabis as Medicine (2005-2007). He has numerous cannabinoid publications, is listed by ISI Web of Knowledge as an “ISI Highly Cited Researcher” (see Pertwee at http://isihighlycited.com/) and was the recipient of the 2002 Mechoulam Award “for his outstanding contributions to cannabinoid research.” His advice about cannabinoids has frequently been sought both nationally and internationally by pharmaceutical companies, government committees, various professional organizations, lawyers, and the press.

Roger Pertwee’s research has focused mainly on the pharmacology of cannabinoids. This research, which began in 1968 at Oxford University and continued when he moved to Aberdeen in 1974, has played major roles in

• the development of cannabinoid bioassays that include the widely used “ring test” and the mouse isolated vas deferens assay;
• the discovery of endocannabinoids and of a CB1 receptor allosteric site;
• the discovery and/or pharmacological characterization both of a number of synthetic cannabinoid receptor agonists and antagonists that are now widely used as research tools and of plant cannabinoids such as Δ9-tetrahydrocannabivarin and cannabidiol;
• the gathering of evidence supporting the use of cannabinoids for the management of multiple sclerosis.

Stephen C. Woods, PhD

Professor Stephen Woods received his PhD in Physiology and Biophysics as well as in Psychology from the University of Washington in 1970, specializing in the endocrinology and neurobiology of ingestive behavior. He was on the faculty at Columbia University and the University of Washington before joining the University of Cincinnati School of Medicine as Professor of Psychiatry and Director of the Obesity Research Center. He is also the Co-Director of the NIH-funded Cincinnati Mouse Diabetes Phenotyping Center.

Professor Woods’s research focuses on the endocrinology and neurobiology of the controls over appetite and food intake, investigating these phenomena using techniques ranging from the molecular, to the physiological, to animal models of ingestive behavior, to clinical applications.  He has authored over 350 scholarly publications, and he received a distinguished MERIT Award for his research on obesity from the NIH. He is a Fellow of the American Association of the Advancement of Science and of the American Psychological Society. He has served as President of the Society for the Study of Ingestive Behavior (SSIB) and the International Congress of the Physiology of Food and Fluid Intake (ICPFFI), and he was on the Executive Board of the North American Society for the Study of Obesity. Dr. Woods is Editor-in-Chief of Physiology and Behavior, and he is on the Editorial Board of the American Journal of Physiology and Diabetes.